A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
- Focus Proof of concept; Therapeutic Use
- 05 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 05 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 09 May 2017 Planned number of patients changed from 12 to 44.